Labetalol (CED0003546)

Labetalol belongs to the benzoic acids and derivatives, a subclass of benzene and substituted derivatives within the organic compounds. This exogenous compound has the formula C19H24N2O3, an average molecular weight of 328.41 g/mol, and exists as a solid at room temperature. It is used as an antihypertensive agent, a sympatholytic agent, an alpha-adrenergic antagonist, and a beta-adrenergic antagonist. In terms of health effects, it is a treatment for hypertension (PMC10298655 , PMC1429741 ) and eclampsia (PMC10298655 , PMC8228929 ). Labetalol targets several proteins, including the alpha-1A, alpha-1B, and alpha-1D adrenergic receptors, as well as the beta-1, beta-2, and beta-3 adrenergic receptors, and heparanase. Labetalol HCl combines nonselective, competitive, beta-adrenergic blocking activity and selective, competitive, alpha-1-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta-blockade have been estimated to be approximately 1:3 following oral administration and 1:7 following intravenous administration. Labetalol contains two asymmetric centers and exists as a molecular complex of two diastereoisomeric pairs, with the R,R' stereoisomer, dilevalol, comprising 25% of racemic labetalol. The compound is recorded in 13 sources, including beta blocking agents, drinking water, indoor air, food preservation, tobacco smoke filters, cigar cigarettes, other smoking requisites, and electrical and electronic equipment such as antennas, electrodes, conductive bodies, hybrid capacitors, and electrically stimulated smoking devices. Recorded exposure routes include oral, intravenous, and inhalation.